Levacetilmetadol [Inn-Spanish] en es it fr

Levacetilmetadol [Inn-Spanish] Brand names, Levacetilmetadol [Inn-Spanish] Analogs

Levacetilmetadol [Inn-Spanish] Brand Names Mixture

  • No information avaliable

Levacetilmetadol [Inn-Spanish] Chemical_Formula


Levacetilmetadol [Inn-Spanish] RX_link


Levacetilmetadol [Inn-Spanish] fda sheet

Levacetilmetadol [Inn-Spanish] msds (material safety sheet)

Levacetilmetadol [Inn-Spanish] Synthesis Reference

No information avaliable

Levacetilmetadol [Inn-Spanish] Molecular Weight

353.498 g/mol

Levacetilmetadol [Inn-Spanish] Melting Point

No information avaliable

Levacetilmetadol [Inn-Spanish] H2O Solubility

>15 mg/mL

Levacetilmetadol [Inn-Spanish] State


Levacetilmetadol [Inn-Spanish] LogP


Levacetilmetadol [Inn-Spanish] Dosage Forms


Levacetilmetadol [Inn-Spanish] Indication

LAAM is indicated for the treatment and management of opiate dependence. It is sometimes used to treat severe pain in terminal patients.

Levacetilmetadol [Inn-Spanish] Pharmacology

LAAM is a synthetic synthetic opioid analgesic with multiple actions quantitatively similar to those as morphine, the most prominent of which involve the central nervous system and organs composed of smooth muscle. However, LAAM is more active and more toxic than morphine. The principal actions of therapeutic value are analgesia and sedation and detoxification or temporary maintenance in narcotic addiction. The LAAM abstinence syndrome, although qualitatively similar to that of morphine, differs in that the onset is slower, the course is more prolonged, and the symptoms are less severe.

Levacetilmetadol [Inn-Spanish] Absorption

LAAM is rapidly absorbed from an oral solution.

Levacetilmetadol [Inn-Spanish] side effects and Toxicity

Signs of overdose include apnea, circulatory collapse, pulmonary edema, cardiac arrest, and death.

Levacetilmetadol [Inn-Spanish] Patient Information

No information avaliable

Levacetilmetadol [Inn-Spanish] Organisms Affected

Humans and other mammals